Quest Launches Pair of Rheumatoid Arthritis Biomarker Tests Based on Protein Licensed from Augurex | GenomeWeb

Quest Diagnostics this week launched a pair of protein biomarker tests for the diagnosis of rheumatoid arthritis.

The tests are based on the 14-3-3eta protein biomarker, which Quest licensed from Canadian biotech firm Augurex. One test consists solely of the 14-3-3eta protein while the other is a panel including both 14-3-3eta and the established RA protein markers anti-cyclic citrullinated peptide antibodies and rheumatoid factor.

Get the full story with
GenomeWeb Premium

Only $95 for the
first 90 days*

A trial upgrade to GenomeWeb Premium gives you full site access, interest-based email alerts, access to archives, and more. Never miss another important industry story.

Try GenomeWeb Premium now.

Already a GenomeWeb Premium member? Login Now.
Or, See if your institution qualifies for premium access.

*Before your trial expires, we’ll put together a custom quote with your long-term premium options.

Not ready for premium?

Register for Free Content
You can still register for access to our free content.